Stelexis Therapeutics procures $43 mln Series A

New York-based Stelexis Therapeutics, a cancer therapeutics firm, has secured $43 million in Series A financing. Stelexis is backed by Deerfield.

8 January 2019•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.